Howe & Rusling’s PDL BioPharma, Inc. PDLI Stock Holding History

Howe & Rusling’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-2,000	Closed	-$6K	–	1013
2018 Q1	$6K	Hold	2,000	–	–	﹤0.01%	594
2017 Q4	$5K	Hold	2,000	–	–	﹤0.01%	580
2017 Q3	$7K	Hold	2,000	–	–	﹤0.01%	540
2017 Q2	$5K	Buy	+2,000	New	+$4.6K	﹤0.01%	655
2015 Q3	–	Sell	-5,138	Closed	-$33K	–	1127
2015 Q2	$33K	Buy	5,138 +119	+2%	+$797	0.01%	344
2015 Q1	$35K	Buy	5,019 +102	+2%	+$739	0.01%	322
2014 Q4	$38K	Buy	4,917 +98	+2%	+$776	0.01%	309
2014 Q3	$36K	Buy	4,819 +74	+2%	+$687	0.01%	322
2014 Q2	$46K	Buy	4,745 +73	+2%	+$651	0.01%	308
2014 Q1	$39K	Buy	4,672 +83	+2%	+$711	0.01%	364
2013 Q4	$39K	Buy	4,589 +83	+2%	+$699	0.01%	329
2013 Q3	$37K	Buy	4,506 +84	+2%	+$675	0.01%	377
2013 Q2	$34K	Buy	+4,422	New	+$34.5K	0.01%	405

Other funds holding PDLI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Howe & Rusling's PDLI Position: Q2 2018 in Review

Howe & Rusling sold out of PDL BioPharma, Inc. (PDLI) in Q2 2018, closing a stake of 2,000 shares — an estimated $6K sold.

Howe & Rusling first reported a position in PDLI in Q2 2013 and held it in 13 quarters. The position peaked at $46K in Q2 2014. 163 funds tracked by Wall St. Rank hold PDLI as of Q2 2018.

Howe & Rusling reported no remaining PDL BioPharma, Inc. position as of Q2 2018 after selling out during the quarter.
Howe & Rusling sold 2,000 PDL BioPharma, Inc. shares in Q2 2018, an estimated $6K.
Howe & Rusling first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 13 quarters.
Howe & Rusling's PDL BioPharma, Inc. position peaked at $46K in Q2 2014.
163 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q2 2018.

Based on Howe & Rusling's 13F filing for Q2 2018, filed 31 Jul 2018.